IL7 GENE INFECTION OF A MURINE FIBROSARCOMA (FSA) ENHANCES TUMOR IMMUNITY (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IL7 GENE INFECTION OF A MURINE FIBROSARCOMA (FSA) ENHANCES TUMOR IMMUNITY (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A1993 1992. Unique Identifier : AIDSLINE ICDB/92684526
McBride WH; Thacker JD; Comora S; Economou J; Hogge D; Dougherty GJ; Dept. of Radiation Oncology, UCLA Sch. of Medicine, Los Angeles,; CA 90024

Abstract: FSA tumor cells that had the mIL7 gene inserted by retrovirus infection (FSA-JmIL7) had decreased tumorigenicity and a high incidence of spontaneous regression. This was associated with a heavy infiltrate of T cells. The number of CD8+ cells was particularly increased, leading to a shift in the balance of CD4:CD8 cells from 1:0.8 in FSA-Jneo to 1:1.6 in FSA-JmIL7. TIL from IL7-producing tumors had greatly enhanced cytotoxicity towards uninfected, parental FSA cells. Killing of non-cross-reacting cells was also increased but to a much lesser extent. There was also an eosinophil/basophil (9-22%) in FSA-JmIL7 that was not present in FSA-Jneo. There were no significant changes in the number of macrophages (10-20%) or B cells (5-8%) as a percentage of total cells, but the ratios of macrophages and B cells to tumor cells were inevitably increased. The number of tumor cells in FSA-JmIL7 varied from 7-33%, presumably reflecting the extent of tumor regression. These findings suggest that IL7 may prove to be a useful cytokine for gene-mediated immunotherapy.
Keywords: Animal B-Lymphocytes/IMMUNOLOGY Cytotoxicity, Immunologic CD4-CD8 Ratio Fibrosarcoma/GENETICS/*IMMUNOLOGY/THERAPY Gene Therapy Immunotherapy Interleukin-7/*GENETICS Macrophages/IMMUNOLOGY Mice T-Lymphocytes, Cytotoxic/IMMUNOLOGY Transfection ABSTRACTKWDanimalb-lymphocytes/immunologycytotoxicity,immunologiccd4-cd8ratiofibrosarcoma/genetics/KWDimmunology/therapygenetherapyimmunotherapyinterleukin-7/KWDgeneticsmacrophages/immunologymicet-lymphocytes,cytotoxic/immunologytransfectionabstract
921030
M92A1036

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .